{
  "docId": "019de074-5234-763a-a0be-96f5f1aa05d9",
  "docSlug": "9279d19020d2e95032dc34a127aaa2e7",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 40,
  "pageCount": 40,
  "prevPage": 39,
  "nextPage": null,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The timeline uses blue and red color coding for different drug programs or status types.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-5234-763a-a0be-96f5f1aa05d9/40",
  "deckHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9",
  "deckJsonHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9.json",
  "deckAnchorHref": "/decks/019de074-5234-763a-a0be-96f5f1aa05d9#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.93,
        "x": 0.035,
        "y": 0.3
      },
      "kind": "diagram",
      "text": "Timeline of clinical milestones from Q4 2022 to H1 2024",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fba9c2d-cf21-4bbd-8f22-945c70e933b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.8,
        "y": 0.3
      },
      "kind": "list",
      "text": "H1 2024: Top line data from CTX-009 US Phase 2/3 BTC Study",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ea7e19f-883b-4822-a030-e7929bd99309",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.65,
        "y": 0.3
      },
      "kind": "list",
      "text": "H2 2023: Top line data from CTX-009 US CRC Phase 2 Study",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1bfbc750-721e-4045-9a05-b93dec8c1d7c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.35,
        "y": 0.3
      },
      "kind": "list",
      "text": "Q1 2023: Initiating CTX-009 US BTC Phase 2/3 Study",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1c5f41e5-7530-49da-9157-8ff4deaedf62",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.2,
        "y": 0.3
      },
      "kind": "list",
      "text": "Q4 2022: Initiated CTX-009 US CRC Phase 2 Study",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "47ab30e7-e04a-4e2c-962f-ea57263bc5be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.35,
        "y": 0.65
      },
      "kind": "list",
      "text": "Q4 2022: Initiated CTX-471 plus PD-1 Study",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f95a28d-8394-47a1-bea8-071288021c15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.75,
        "y": 0.65
      },
      "kind": "list",
      "text": "H2 2023: Initiate CTX-8371 Phase 1 Study",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69cfca2e-3dc9-4e1b-bd51-d084b4237cb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.2,
        "y": 0.65
      },
      "kind": "list",
      "text": "Q4 2022: Completed the ongoing CTX-471 Phase 1b study",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99dcb125-7b55-4eaa-a9f6-02a7c648024d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.5,
        "y": 0.3
      },
      "kind": "list",
      "text": "H1 2023: CTX-8371 IND filing",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bbd94aac-bd42-4de6-9321-543005ea7593",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.6,
        "y": 0.65
      },
      "kind": "list",
      "text": "H2 2023: Initiate CTX-009 U.S. Ovarian /other Phase 2 Study",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e85ebad9-328f-4932-a83c-5855035ac5d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.38,
        "x": 0.035,
        "y": 0.075
      },
      "kind": "title",
      "text": "Key 12 Month Milestones",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c34fd19-5529-43e7-9d73-309a96d3a099",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "47da655a-0b68-4301-8c37-b762fc20b8c1",
      "evidence": "Chronological sequence of clinical milestones",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 40,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f0a32b3c-a238-480c-9a9d-c05166154467",
      "evidence": "The document implies that the current state of cancer treatment is inadequate and that innovative therapies are needed.",
      "position": 0,
      "objective": "The cost of inaction in cancer treatment",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 40,
      "from": 7,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "6979bcd9-f71b-4757-b297-1c4753563587",
      "evidence": "The document presents data and results for each of these therapies.",
      "position": 1,
      "objective": "The potential benefits of CTX-009, CTX-471, and CTX-8371",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}